Lanlan Ru

Title: Innovations in Genetic Detection: The Contributions of Lanlan Ru

Introduction

Lanlan Ru is a noted inventor based in Beijing, China, recognized for his groundbreaking work in the field of genetic diagnostics. With a focus on non-invasive methods for detecting genetic mutations, his contributions are particularly significant in the realm of cancer research and treatment. Ru's innovative approach aims to provide efficient and accurate identification of genetic anomalies, which can ultimately lead to better patient outcomes.

Latest Patents

Ru holds a patent for a "Method and kit for non-invasively detecting EGFR gene mutations." This invention advances the field by offering a method that includes several meticulously designed steps: First, primers are designed according to EGFR gene exons. Next, plasma DNAs are extracted from subjects and connected with tagging linkers. The extracted plasma DNAs undergo PCR pre-amplification, followed by cyclization to yield cyclized DNAs. The final steps involve PCR amplification of these cyclized DNAs using the designed primers and subsequent high-throughput sequencing of the amplified products to analyze EGFR gene mutations. This innovative methodology, complemented by an accompanying kit, represents a significant leap in non-invasive genetic testing.

Career Highlights

Lanlan Ru is affiliated with Berry Genomics Co., Ltd., a prominent company specializing in genomic information technology. His work at Berry Genomics focuses on enhancing diagnostic methods and contributing to the advancement of personalized medicine. The effectiveness of his innovations is rooted in the collaboration and expertise within the team from Berry Genomics.

Collaborations

Among Ru's coworkers are notable professionals such as Lina Wang and Tiancheng Li. The synergy among these talented individuals fosters an environment of creativity and innovation, leading to groundbreaking advancements in genomic research and applications.

Conclusion

Lanlan Ru’s work exemplifies the potential of innovative methodologies in the detection of genetic mutations. By combining meticulous scientific processes with collaboration at Berry Genomics, he continues to make significant strides in improving non-invasive diagnostic techniques. His contributions not only enhance our understanding of EGFR gene mutations but also pave the way for better diagnostic and therapeutic options for patients worldwide.